Ilika plc Q&A with Dr Tom McColm at Baden Hill (LON:IKA)

Ilika Plc

Ilika plc (LON:IKA) is the topic of conversation when Baden Hill’s Partner and Equity Specialist Dr Tom McColm caught up with DirectorsTalk for an exclusive interview.

Q1: We’ve just seen that Ilika has published final results which were looking pretty good, where do you see the company’s first OEM licencing deal coming from?

A1: Yes, it’s a good question, it’s the thing that everyone’s looking for. I actually think it’ll be from one of the more specialised small scale Stereax applications and even though it was their latest and most recent product launch, the M50, this very very small millimetre scale device.

I think it will come for that product in the medical device application area because it’s such a high value add and there isn’t really any other batteries that can perform those sort of functions.

So, if I was a betting man, I’d say it’ll be an M50 application and what it definitely won’t be will be the big goliath cells in EV, I think that’s still a long way off.

Q2: So, what should investors be looking out for news flow wise over the next 12 months?

A2: Obviously, the one that I mentioned earlier, is we’re looking for this first big OEM licencing deal, it does seem like they’re getting closer and closer in a number of areas so that one will be a bit of a game changer.

Also, an important area is the relationship that they have with Semefab on the manufacturing side, information on that will be interesting, how that’s going, how that scale-up’s going because without that, the whole business model won’t work.

So, big first OEM licencing deal and good progress on the manufacturing partnership with Semefab.

Q3: Finally, what’s your view on the overall global battery market going forward?

A3: I think it’s just going to absolutely going to get massive. There’s two huge global megatrends at the moment, you’ve got the decarbonisation of energy and you’ve got the electrification of transport, both of those require vast amounts of storage.

Alongside that, you’ve still got the usual markets, consumer electronics markets, mobile phones etc. so I think there’s going to be a huge growth in the volume of batteries produced over the next 10/20 years.

Ilika plc is a pioneer in solid state battery technology. Ilika’s Stereax® state batteries include miniaturised products for powering wireless sensors in applications ranging from hostile industrial environments to medical implants.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Dr Tom McColm on Ilika: Stereax revenues and Goliath milestones (LON:IKA)

Clean-tech equities specialist Dr Tom McColm reviews Ilika’s interim results, highlighting stable cash levels, the first recurring commercial revenues from Stereax, and continued technical and manufacturing progress on the Goliath battery platform.

Ilika CEO Graeme Purdy on Stereax and Goliath progress (LON:IKA)

Graeme Purdy, CEO of Ilika, outlines progress in manufacturing readiness and early customer shipments for the Stereax miniature solid-state battery, as well as ongoing grant-supported development and customer engagement for the Goliath EV battery programme.

Ilika moves into commercial phase with first Stereax electrode order

Ilika has received its first commercial order for Stereax battery electrodes, marking the start of scaled production for medical device applications.

Ilika plc: First Commercial Revenues Signal Pivotal Shift in Solid-State Battery Journey (Video)

Ilika plc has crossed a commercial milestone with its first regular revenue stream from its Stereax battery line, according to Dr Tom McColm of Morphose Capital. With strong cash reserves, momentum on its Goliath platform, and growing interest from defence sectors, the next 12 months could be transformational.

Ilika Plc: Solid-State Breakthroughs Put Stereax and Goliath in the Spotlight (Video)

Ilika CEO Graeme Purdy shares how the company has shifted from commissioning to customer deliveries of its Stereax batteries — and why its Goliath EV programme is designed to beat the commoditised market with faster charging and extended range.

Ilika reports on-track progress across Stereax and Goliath in H1 2025/26

Ilika reports unaudited half-year results to 31 October 2025, highlighting on-schedule delivery of key commercial milestones across its Stereax medical battery and Goliath EV battery programmes, alongside continued customer validation, pilot-line commissioning, and £4.2m fundraising to support its roadmap.

Search

Search